News

Luminoah Announces FDA Clearance of the Luminoah Flow Enteral Nutrition System, A Brighter Future for Tube Feeding

Luminoah, a medical technology company focused on modernizing enteral nutrition, today announced it has received U.S. Food and Drug Administration clearance for Luminoah Flow™, an enteral feeding system designed to improve the experience of patients who rely on tube feeding.

Luminoah Flow combines portability, precision, and connected technology into a streamlined system designed for both patients and clinicians. It provides access to real time data, simplifies workflows, and features a design intended to improve mobility and independence.

For Luminoah founder Neal Piper, this milestone reflects six years of innovation shaped by personal experience with enteral nutrition during his son’s cancer treatment.

“FDA clearance of Luminoah Flow marks a major milestone in our mission to transform enteral nutrition,” said Neal Piper, Founder and Chief Executive Officer of Luminoah. “Inspired by my family’s experience, we built Luminoah to address persistent challenges faced by patients and caregivers. Patients living with feeding tubes need solutions that integrate more naturally into daily life, and Luminoah Flow brings together modern technology and patient centered design to better support patients, caregivers, and clinicians.”

“One of the biggest gaps in enteral care today is limited visibility once patients leave the hospital,” said Dr. Gary Nace Jr., Pediatric Surgeon at Children’s Hospital of Philadelphia. “Clinicians often rely on reported information rather than objective data when managing nutrition outside the hospital. A system like Luminoah Flow may help provide greater visibility into what is being delivered at home and support more informed clinical decision making.”

“Enteral nutrition is a critical therapy for millions of patients, yet the technology supporting it has changed very little over time,” said Tegan Medico, MS, MPH, RDN, CNSC, Clinical Dietitian at UVA Health. “Much of the burden still falls on patients and caregivers to manage feeds and communicate what is happening at home. A system like Luminoah Flow may help bring greater simplicity and visibility to that process, allowing clinicians to better support patients between visits.”

Key Features of Luminoah Flow Include:

  • Compact, lightweight design that enhances mobility and discretion

  • Real time data tracking to support visibility into nutrition delivery

  • Modern touchscreen pump interface for both patients and caregivers

  • Eco-friendly USB-C charging capability for flexibility and convenience

“This clearance reflects the work our team has put into solving a deeply important problem,” said Garrett Marin, Chief Operating Officer at Luminoah. “We are excited to bring a solution to market that meets regulatory standards while improving day to day care for patients and providers.”

Luminoah plans to begin a phased commercial rollout of Luminoah Flow across the United States, working closely with healthcare providers, home health organizations, and patient communities.

Read more here.

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He